CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended				59 Months Ended
	Mar. 31, 2012		Mar. 31, 2011		Mar. 31, 2012
Revenue
Operating expense
General & administrative	231,314	[1]	350,238	[1]	6,304,678	[1]
Total operating expense	522,627		592,737		10,388,627
Net operating loss	(522,627)		(592,737)		(10,388,627)
Other income (expense)
Interest income	529		191		76,839
Other income					244,479
Other expense	(129)		(180)		(3,665)
Total Other Income (Expense)	400		11		317,653
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest, Total	(522,227)		(592,726)		(10,070,974)
Net loss per share, basic and diluted	$ (0.01)		$ (0.01)		$ (0.23)
Basic and diluted weighted average number of common shares outstanding	58,381,419		49,400,605		43,972,871
All Other
Operating expense
Research and development	279,613	[2]	192,499	[2]	3,472,499	[2]
MD Anderson for License
Operating expense
Research and development	$ 11,700	[3]	$ 50,000	[3]	$ 611,450	[3]

[1] General & administrative expense includes stock option expense of $1,950 and $104,726 for the quarters ending 3/31/2012 and 3/31/2011, respectively; and for the period from inception through 3/31/2012, $2,582,964 for stock option and warrant expense and $300,000 in stock for services.

[2] Research and development expense includes stock option expense of $17,406 and $15,205 for the quarters ending 3/31/2012 and 3/31/2011, respectively; and $386,761 for the period from inception through 3/31/2012. Research and development expense also includes amortization expense of $48,109 and $51,756 for the quarters ending 3/31/2012 and 3/31/2011, respectively; and $839,572 for the period from inception through 3/31/2012.

[3] Includes $345,000 technology impairment charge for the period from inception through 3/31/2012.